Clinical Trial: Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer

U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489300) titled 'Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer' on March 19.

Brief Summary: Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China

Study Start Date: March 30

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer Fallopian Tube Cancers Primary Peritoneal Cancer

Intervention: DRUG: Benmelstobart in combination with Anlotinib and or...